IL215165A - Method for preparing a site-specific physiologically active polypeptide conjugate - Google Patents
Method for preparing a site-specific physiologically active polypeptide conjugateInfo
- Publication number
- IL215165A IL215165A IL215165A IL21516511A IL215165A IL 215165 A IL215165 A IL 215165A IL 215165 A IL215165 A IL 215165A IL 21516511 A IL21516511 A IL 21516511A IL 215165 A IL215165 A IL 215165A
- Authority
- IL
- Israel
- Prior art keywords
- site
- preparing
- physiologically active
- active polypeptide
- polypeptide conjugate
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20090023953 | 2009-03-20 | ||
| PCT/KR2010/001674 WO2010107256A2 (en) | 2009-03-20 | 2010-03-18 | Method for preparing a site-specific physiologically active polypeptide conjugate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL215165A0 IL215165A0 (en) | 2011-12-29 |
| IL215165A true IL215165A (en) | 2016-11-30 |
Family
ID=42740133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL215165A IL215165A (en) | 2009-03-20 | 2011-09-15 | Method for preparing a site-specific physiologically active polypeptide conjugate |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8895281B2 (en) |
| EP (1) | EP2408800B1 (en) |
| JP (2) | JP5759976B2 (en) |
| KR (1) | KR101164453B1 (en) |
| CN (1) | CN102369209B (en) |
| AR (1) | AR075913A1 (en) |
| AU (1) | AU2010225523B2 (en) |
| BR (1) | BRPI1013626B8 (en) |
| CA (1) | CA2755395C (en) |
| DK (1) | DK2408800T3 (en) |
| ES (1) | ES2587397T3 (en) |
| HR (1) | HRP20161055T1 (en) |
| HU (1) | HUE030373T2 (en) |
| IL (1) | IL215165A (en) |
| MX (1) | MX2011009803A (en) |
| MY (1) | MY150536A (en) |
| NZ (1) | NZ595848A (en) |
| PL (1) | PL2408800T3 (en) |
| PT (1) | PT2408800T (en) |
| RU (1) | RU2495881C2 (en) |
| SG (1) | SG174320A1 (en) |
| TW (1) | TWI472342B (en) |
| WO (1) | WO2010107256A2 (en) |
| ZA (1) | ZA201107658B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101511660B1 (en) * | 2010-10-08 | 2015-04-13 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | Peptide derivative and use thereof |
| US9278146B2 (en) | 2010-10-08 | 2016-03-08 | Kyoto University | Peptide derivative and use of the same |
| CN102675452B (en) * | 2011-03-17 | 2015-09-16 | 重庆富进生物医药有限公司 | Tool continues the conjugate of insulin human that is hypoglycemic and that combined by height and analogue |
| CN106928341B (en) * | 2011-03-30 | 2021-06-01 | 上海仁会生物制药股份有限公司 | Fixed-point mono-substituted pegylated Exendin analogue and preparation method thereof |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| KR102092206B1 (en) * | 2011-06-02 | 2020-03-24 | 옵코 바이오로직스 리미티드 | Long-acting glp-1/glucagon receptor agonists |
| UA126465C2 (en) * | 2011-06-10 | 2022-10-12 | Ханмі Сайенс Ко., Лтд. | A peptide having oxyntomodulin activity and a pharmaceutical composition for the treatment of obesity containing it |
| RU2607365C2 (en) * | 2011-06-17 | 2017-01-10 | Ханми Сайенс Ко., Лтд. | Conjugate, containing oxyntomodulin and fragment of immunoglobulin, and use thereof |
| KR20130049671A (en) * | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | Method for preparation of biological active polypeptide conjugate |
| KR101895047B1 (en) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | A site-specific GLP-2 conjugate using an immunoglobulin fragment |
| AR090281A1 (en) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX |
| EA201492269A1 (en) | 2012-06-04 | 2016-02-29 | Опко Байолоджикс Лтд. | PEDIED OXM OPTIONS |
| KR101968344B1 (en) * | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | A composition for treating hyperlipidemia comprising oxyntomodulin analog |
| KR101993393B1 (en) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | A composition for treating diabetes or diabesity comprising oxyntomodulin analog |
| WO2014073842A1 (en) | 2012-11-06 | 2014-05-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| KR20140088837A (en) * | 2013-01-03 | 2014-07-11 | 한미약품 주식회사 | Insulinotropic peptide derivative wherein its N-terminal charge is modified |
| MX361083B (en) * | 2013-02-26 | 2018-11-27 | Hanmi Pharma Co Ltd | Site-specific insulin conjugate. |
| AR096891A1 (en) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME |
| CN103804483A (en) * | 2014-03-13 | 2014-05-21 | 中国人民解放军第四军医大学 | Orexin-A pegylation modifier and preparation method thereof |
| KR20150140177A (en) * | 2014-06-05 | 2015-12-15 | 한미약품 주식회사 | Method of decreasing immunogenicity of protein and pepteide |
| TWI802396B (en) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
| KR102418477B1 (en) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | Gluagon Derivatives |
| US11123436B2 (en) | 2015-07-24 | 2021-09-21 | Hanmi Pharm. Co., Ltd. | Method of preparing physiologically active polypeptide conjugate |
| WO2017052329A1 (en) * | 2015-09-24 | 2017-03-30 | Hanmi Pharm. Co., Ltd. | Protein complex by use of a specific site of an immunoglobulin fragment for linkage |
| KR101974305B1 (en) * | 2018-02-14 | 2019-04-30 | 한미사이언스 주식회사 | Method for preparation of biological active polypeptide conjugate |
| US12441776B2 (en) | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| CN109678930B (en) * | 2018-12-05 | 2022-04-29 | 西北工业大学 | Polyethylene glycol modified NPFF and its use |
| CN109535244B (en) * | 2018-12-11 | 2020-12-01 | 上海景峰制药有限公司 | Purification method of recombinant human brain natriuretic peptide |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2204726A1 (en) * | 1994-11-09 | 1996-12-27 | Robin E. Offord | Functionalized polymers for site-specific attachment |
| EP0922446A1 (en) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
| US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| CA2372214A1 (en) | 1999-04-30 | 2000-11-09 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| CA2422707A1 (en) * | 2000-10-05 | 2002-04-11 | Ares Trading S.A. | Regioselective liquid phase pegylation |
| US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| US8423976B2 (en) * | 2003-03-13 | 2013-04-16 | Northrop Grumman Corporation | Extreme pipeline and optimized reordering technology |
| JP2006520818A (en) * | 2003-03-19 | 2006-09-14 | イーライ リリー アンド カンパニー | Polyethylene glycol-linked GLP-1 compound |
| KR100507796B1 (en) | 2003-04-03 | 2005-08-17 | 한미약품 주식회사 | Peg-biologically active polypeptide homodimer conjugate having enhanced half life in blood and process for the preparation thereof |
| DK2599502T3 (en) * | 2003-04-11 | 2017-04-18 | Antriabio Inc | Process for Preparation of Site-Specific Protein Conjugates |
| BRPI0413644A (en) | 2003-08-21 | 2006-10-17 | Novo Nordisk As | methods for separating the two forms of a polypeptide having a single amino acid racemization, and for separating two polypeptides, polypeptide product, and pharmaceutical composition |
| PT2363414T (en) * | 2004-11-12 | 2022-08-04 | Bayer Healthcare Llc | Site-directed modification of fviii |
| WO2006076471A2 (en) * | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
| US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| WO2008051383A2 (en) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Use of alcohol co-solvents to improve pegylation reaction yields |
| JP2009019027A (en) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | Insulin-secreting peptide derivatives with amino-terminal amino acid mutations |
-
2010
- 2010-03-18 MX MX2011009803A patent/MX2011009803A/en active IP Right Grant
- 2010-03-18 AU AU2010225523A patent/AU2010225523B2/en active Active
- 2010-03-18 KR KR1020100024312A patent/KR101164453B1/en active Active
- 2010-03-18 BR BRPI1013626A patent/BRPI1013626B8/en active IP Right Grant
- 2010-03-18 PT PT107537060T patent/PT2408800T/en unknown
- 2010-03-18 HU HUE10753706A patent/HUE030373T2/en unknown
- 2010-03-18 US US13/255,199 patent/US8895281B2/en active Active
- 2010-03-18 WO PCT/KR2010/001674 patent/WO2010107256A2/en not_active Ceased
- 2010-03-18 EP EP10753706.0A patent/EP2408800B1/en active Active
- 2010-03-18 CN CN201080012890.8A patent/CN102369209B/en active Active
- 2010-03-18 ES ES10753706.0T patent/ES2587397T3/en active Active
- 2010-03-18 HR HRP20161055TT patent/HRP20161055T1/en unknown
- 2010-03-18 DK DK10753706.0T patent/DK2408800T3/en active
- 2010-03-18 JP JP2012500720A patent/JP5759976B2/en active Active
- 2010-03-18 NZ NZ595848A patent/NZ595848A/en not_active IP Right Cessation
- 2010-03-18 CA CA2755395A patent/CA2755395C/en active Active
- 2010-03-18 MY MYPI2011004374 patent/MY150536A/en unknown
- 2010-03-18 SG SG2011065166A patent/SG174320A1/en unknown
- 2010-03-18 PL PL10753706.0T patent/PL2408800T3/en unknown
- 2010-03-18 RU RU2011142332/04A patent/RU2495881C2/en active
- 2010-03-19 TW TW99108144A patent/TWI472342B/en not_active IP Right Cessation
- 2010-03-22 AR ARP100100911A patent/AR075913A1/en not_active Application Discontinuation
-
2011
- 2011-09-15 IL IL215165A patent/IL215165A/en active IP Right Grant
- 2011-10-19 ZA ZA2011/07658A patent/ZA201107658B/en unknown
-
2015
- 2015-03-02 JP JP2015040382A patent/JP2015127330A/en not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL215165A0 (en) | Method for preparing a site-specific physiologically active polypeptide conjugate | |
| IL259869B (en) | A process for preparing a purified conjugate in a solution | |
| IL237642A (en) | Method for preparing pharmaceutical agents | |
| GB0906065D0 (en) | Delivery system for a prosthesis | |
| GB2474363B (en) | System for tensioning a surgical wire | |
| PL2952125T3 (en) | Capsule for preparing a beverage | |
| SG10201403309WA (en) | System, capsule and method for preparing a beverage | |
| ZA201200317B (en) | System, method and capsule for preparing a beverage | |
| ZA201208940B (en) | Brewing apparatus for ectracting a portion capsule | |
| GB0903247D0 (en) | Support structure implant for a bone cavity | |
| SI2413753T1 (en) | Machine for preparing coffee | |
| ZA201403189B (en) | Method for preparing physiologically active polypeptide complex | |
| PT2430017T (en) | A method for preparing amorphous silibinin | |
| IL219948A0 (en) | Polypeptide conjugate | |
| IL215183A0 (en) | Process for preparing (r)-7v-benzyl-2-(benzyloxycarbonylamino)-s-methoxypropionamide | |
| IL213364A0 (en) | Process for preparing olopatadine and/or a pharmaceutically acceptable salt thereof | |
| PL2506971T3 (en) | Method for preparing a deperoxidation catalyst | |
| PT2952125T (en) | Capsule for preparing a beverage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |